WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MAY ISSUE PUBLISHED
  • May Issue has been successfully launched on 1 May 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

USING OF NEFOPAM FOR MANGMENT POST OPERATIVE SHIVERING AND PREVENTION OF PAIN

Dr. Duraid Husam Mohammad Saeed*

ABSTRACT

Although the mechanism of action of nefopam hydrochloride, a non-opioid analgesic, is not fully understood, it is widely accepted that it acts centrally. Post-operative pain, dental and musculoskeletal discomfort, acutely traumatic pain, and cancer pain are among the conditions for which it is prescribed. It may also play a role in the treatment of chronic pain that is not responsive to conventional opioid analgesics. Only a few studies have looked at the effectiveness of nefopam in treating acute and chronic pain. SIGN 136, Management of chronic pain, December 2013 backs this up, stating that there is not enough evidence to support the use of nefopam in the treatment of chronic pain. Codeine or co-codamol 30/500, the first line of treatment for moderate pain, is significantly less expensive than nefopam pills. Tayside is one of Scotland's largest consumers. Implementation In order to enhance prescription, nefopam has been converted to an amber traffic light (GP under the direction of a specialist) on the Tayside Formulary and patients currently on nefopam should be assessed with the goal of quitting or switching to 1st line alternatives if necessary. Prescribers should take action Using the nefopam protocol as a guide, review patients currently taking nefopam for effectiveness. Overleaf, you'll find a sample of my work. It should only be prescribed for individuals who are unable or unwilling to take codeine, tramadol, or NSAIDS, or who are unable or unable to take powerful opioids. The Tayside Guidance should be followed if the patient has neuropathic symptoms. Chronic neuropathic pain treatment 4). Treatment should be reassessed often (every 2 to 4 weeks) and halted if short-term gains are not observed. Considerable points to keep in mind. 1). Overdosage of nefopam can be fatal. Convulsions, hallucinations, agitation, and tachycardia are all possible symptoms. 2). Nausea, urine retention, dry mouth, dizziness, and nervousness are all common adverse effects. Clinical cases of hyponatremia have been documented. People with convulsive disorders should not take this medication. In the elderly, exercise caution to prevent confusion. Consider your anticholinergic burden. A typical oral dose ranges from 30 to 90mg three times daily.

Keywords: .


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More